Drugs / ENERGI-F705
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07647614 | Dec 2026 → Jan 2030 expected | Parkinson disease | Energenesis Biomedical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07650383 Comparator | Feb → May 2025 | — | Energenesis Biomedical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENERGI-F705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07647614 ↗ |
| Route | Oral | “Tablets will be taken orally twice a day” NCT07647614 ↗ |